Literature DB >> 20047900

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Samira Saadoun1, Patrick Waters, B Anthony Bell, Angela Vincent, A S Verkman, Marios C Papadopoulos.   

Abstract

Neuromyelitis optica is an inflammatory demyelinating disease of the central nervous system associated with autoantibodies against the glial water channel protein aquaporin-4. It has recently been reported that immunoglobulin from neuromyelitis optica patients injected peripherally does not cause lesions in naive rats, but only when pre-existing central nervous system inflammation is present. Here, we investigated whether immunoglobulin G from aquaporin-4-autoantibody-positive neuromyelitis optica patients has the potential to damage the central nervous system either alone or in the presence of human complement. Immunoglobulin G from neuromyelitis optica patients did not activate mouse complement and was not pathogenic when injected into mouse brain. However, co-injection of immunoglobulin G from neuromyelitis optica patients with human complement produced neuromyelitis optica-like lesions in mice. Within 12 h of co-injecting immunoglobulin G from neuromyelitis optica patients and human complement, there was a striking loss of aquaporin-4 expression, glial cell oedema, myelin breakdown and axonal injury, but little intra-parenchymal inflammation. At 7 days, there was extensive inflammatory cell infiltration, perivascular deposition of activated complement components, extensive demyelination, loss of aquaporin-4 expression, loss of reactive astrocytes and neuronal cell death. In behavioural studies, mice injected with immunoglobulin G from neuromyelitis optica patients and human complement into the right hemisphere preferentially turned to the right at 7 days. No brain inflammation, demyelination or right-turning behaviour was seen in wild-type mice that received immunoglobulin G from non-neuromyelitis optica patients with human complement, or in aquaporin-4-null mice that received immunoglobulin G from neuromyelitis optica patients with human complement. We conclude that co-injection of immunoglobulin G from neuromyelitis optica patients with human complement reproduces the key histological features of neuromyelitis optica and that aquaporin-4 is necessary and sufficient for immunoglobulin G from neuromyelitis optica patients to exert its effect. In our mouse model, immunoglobulin G from neuromyelitis optica patients does not require pre-existing central nervous system inflammation to produce lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047900      PMCID: PMC2822632          DOI: 10.1093/brain/awp309

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  23 in total

1.  Direct immunogold labeling of connexins and aquaporin-4 in freeze-fracture replicas of liver, brain, and spinal cord: factors limiting quantitative analysis.

Authors:  J E Rash; T Yasumura
Journal:  Cell Tissue Res       Date:  1999-05       Impact factor: 5.249

2.  Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4.

Authors:  T Ma; B Yang; A Gillespie; E J Carlson; C J Epstein; A S Verkman
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

3.  Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption.

Authors:  Samira Saadoun; Marios C Papadopoulos; Mariko Hara-Chikuma; A S Verkman
Journal:  Nature       Date:  2005-04-07       Impact factor: 49.962

4.  Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  T Misu; K Fujihara; A Kakita; H Konno; M Nakamura; S Watanabe; T Takahashi; I Nakashima; H Takahashi; Y Itoyama
Journal:  Brain       Date:  2007-04-02       Impact factor: 13.501

5.  Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.

Authors:  Jeffrey L Bennett; Chiwah Lam; Sudhakar Reddy Kalluri; Philippe Saikali; Katherine Bautista; Cecily Dupree; Magdalena Glogowska; David Case; Jack P Antel; Gregory P Owens; Don Gilden; Stefan Nessler; Christine Stadelmann; Bernhard Hemmer
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

6.  Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

Authors:  Monika Bradl; Tatsuro Misu; Toshiyuki Takahashi; Mitsutoshi Watanabe; Simone Mader; Markus Reindl; Milena Adzemovic; Jan Bauer; Thomas Berger; Kazuo Fujihara; Yasuto Itoyama; Hans Lassmann
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

7.  In vivo demyelinating activity of sera from animals with chronic experimental allergic encephalomyelitis. Antibody nature of the demyelinating factor and the role of complement.

Authors:  H Lassmann; H Stemberger; K Kitz; H M Wisniewski
Journal:  J Neurol Sci       Date:  1983-04       Impact factor: 3.181

8.  Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.

Authors:  Shanu F Roemer; Joseph E Parisi; Vanda A Lennon; Eduardo E Benarroch; Hans Lassmann; Wolfgang Bruck; Raul N Mandler; Brian G Weinshenker; Sean J Pittock; Dean M Wingerchuk; Claudia F Lucchinetti
Journal:  Brain       Date:  2007-02-04       Impact factor: 13.501

9.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

Review 10.  NMO-IgG: a specific biomarker for neuromyelitis optica.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Dis Markers       Date:  2006       Impact factor: 3.434

View more
  210 in total

Review 1.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

2.  Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report.

Authors:  Masahiro Mori; Naoki Kawaguchi; Akiyuki Uzawa; Yuhko Nemoto; Saeko Masuda; Satoshi Kuwabara
Journal:  J Neurol       Date:  2011-11-08       Impact factor: 4.849

3.  Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain.

Authors:  Samira Saadoun; Patrick Waters; Claire MacDonald; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Ann Neurol       Date:  2012-02-28       Impact factor: 10.422

Review 4.  The adaptive immune system in diseases of the central nervous system.

Authors:  David C Wraith; Lindsay B Nicholson
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 5.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

6.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

7.  Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.

Authors:  Julien Ratelade; Nithi Asavapanumas; Alanna M Ritchie; Scott Wemlinger; Jeffrey L Bennett; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-08-31       Impact factor: 17.088

8.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

9.  Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Xiaoming Yao; Tao Su; Alex J Smith; Alan S Verkman
Journal:  Acta Neuropathol       Date:  2017-05-31       Impact factor: 17.088

10.  Review of Animal Models of Neuromyelitis Optica.

Authors:  Melina V Jones; Nicolas Collongues; Jerome de Seze; Makoto Kinoshita; Yuji Nakatsuji; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.